Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

OSE 2101

X
Drug Profile

OSE 2101

Alternative Names: EP-2101; IDM 2101; OSE-2101; Tedopi

Latest Information Update: 03 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IDM Pharma
  • Developer Bristol-Myers Squibb; GERCOR; OSE Immunotherapeutics
  • Class Antineoplastics; Cancer vaccines; Immunotherapies
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Non-small cell lung cancer
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Colorectal cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer

Most Recent Events

  • 03 Apr 2024 US FDA approved two dossiers for OSE 2101 in Non-small cell lung cancer
  • 27 Mar 2024 OSE Immunotherapeutics announces intention to submit a dossier to Europe in December 2024
  • 19 Jan 2024 Dossier receives positive review from the US FDA for OSE 2101 in Non-small cell lung cancer, before January 2024
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top